BenzingaT3·8mo ago
VTYX Ventyx Biosciences, Inc. Common Stock
XNAS
14.00
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
VTYX
$14.00
—
Key stats
$14.00
- 52-Week Range
- $3.41 – $25.00
- YTD
- +66.61%
- Straddle Price
- $2.48
- P/C Vol Ratio
- 3.96
- Market Cap
- $1.0B
- Open
- $13.99
- Day Range
- $13.99 – $13.99
- Prev Close
- $13.99
Fair Value
-2.6% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.00% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.50% (VRP-adj) |
| WACC | 9.50% |
| Volatility Risk Premium | +454.8pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Quality Score | 0/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $13.63 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $13.98 |
| Bollinger Width / SMA20 | 3.1% (drives anchor stability) |
| Net Debt | $0.0B |
Blended Fair Value
$13.63
Deviation
-2.6%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | n/a | 0% | |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $13.63 | 100% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-01 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.0B
- Employees
- 81
- List Date
- 2021-10-21
- CIK
- 0001851194
- Headquarters
- San Diego, CA
- Homepage
- https://www.ventyxbio.com
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition a…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
Insufficient price history — listed 1827 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $13.98
SMA 50: $13.63
SMA 200: $6.90
Current: $13.99
EMA 12: $13.98
EMA 26: $13.83
MACD: 0.1512 | Signal: -0.0619
BULLISH
ADX (14): 71.15
STRONG TREND
+DI: 49.78
−DI: 8.05
Momentum Oscillators
RSI (14): 71.73
OVERBOUGHT
Stoch %K: 79.44
Stoch %D: 81.67
Williams %R: -25.00
Volume & Volatility
BB Upper: $14.01
BB Lower: $13.95
NEUTRAL
OBV: 225,729,241
Vol SMA 20: 2,296,100
Vol ROC: -100.00%
ATR: $0.09
True Range: $0.00
HV 20: 1.1%
HV 30: 1.8%
HV 60: 90.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-03-18T00:00:00 – 2026-03-16T00:00:00
AI Analysis
LLM Stock Analysis Report - VTYX
Executive Summary
Confidence Level: 7/10 (Neutral)
Key Drivers:
- Technical indicators suggest a strong uptrend, with the MACD generating a bullish signal.
- Recent news headlines have been negative, potentially weighing on the stock price.
Primary Risks:
- High volatility may lead to increased uncertainty and trading ranges.
- Negative sentiment from recent news headlines could impact investor confidence.
Investment Thesis: VTYX is a high-volatility stock with an uptrend supported by technical indicators. However, recent negative news headlines have created uncertainty, making it essential to monitor the situation closely.
Recent News Sentiment Impact: The negative news headlines have likely contributed to the current trading range and volatility. A turnaround in sentiment could trigger a potential breakout or breakdown.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Bullish
- Long-term (3-12 months): Neutral
Support/Resistance Levels:
- Key price levels from moving averages:
- SMA 20: $13.98
- SMA 50: $13.63
- Technical patterns:
- Upper Bollinger Band: $14.01
- Middle Bollinger Band: $13.98
Momentum Signals:
- RSI interpretation: Overbought (>70)
- MACD signal: Bullish (0.15 / Signal: -0.06 / Histogram: 0.21)
- Bollinger Bands position: Neutral (squeeze)
Volume Analysis: Volume trends suggest institutional interest and trading activity, with a volume rate of change indicating a decrease in trading intensity.
News & Sentiment Analysis
Recent Headlines Summary:
The recent news headlines have been largely negative, focusing on mergers and acquisitions, shareholder alerts, and investigations. This sentiment has likely contributed to the current volatility and uncertainty.
Sentiment Assessment: Negative
Catalyst Identification: No significant catalysts announced recently, but upcoming events could impact the stock price.
Market Narrative: The negative news headlines have created a challenging environment for investors, with potential for increased volatility. A turnaround in sentiment could trigger a breakout or breakdown.
Risk & Volatility Assessment
Beta Interpretation: High risk (beta >1.51)
Volatility Regime: Current vs historical volatility levels: + Historical: 90.9% (HV60) + Current: 173.4%
Options Market Signals: IV rank: Low (18.0%), put/call ratio: Bearish sentiment
Downside Protection: Support levels and risk management considerations are essential to protect against potential losses.
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: + Sector: Neutral + Market: Negative
Institutional Activity: Volume patterns suggest institutional interest and trading activity, with a volume rate of change indicating a decrease in trading intensity.
Correlation Analysis: How stock moves relative to market (R-squared interpretation): + Correlation: 0.13 + Interpretation: Low correlation between VTYX and the broader market
Relative Valuation: Position within trading range: + Currently trading below the upper Bollinger Band ($14.01)
Key Levels & Action Items
Critical Price Levels:
- Support level: SMA 50 ($13.63)
- Resistance level: Upper Bollinger Band ($14.01)
Breakout/Breakdown Levels: No significant levels announced recently.
Time-Sensitive Catalysts: No upcoming events or announcements scheduled.
Risk Management: Stop-loss levels and position sizing considerations are essential to protect against potential losses.
Please note that this analysis is based on the data provided, and actual market conditions may differ. It's crucial to monitor recent news headlines, technical indicators, and volatility metrics to adjust the analysis accordingly.
Generated
News
All VTYX news →
GlobeNewswire Inc.T3·8mo ago
BenzingaT3·9mo ago
GlobeNewswire Inc.T3·9mo ago
GlobeNewswire Inc.T3·9mo ago
GlobeNewswire Inc.T3·9mo ago
Investing.comT3·9mo ago
GlobeNewswire Inc.T3·9mo ago
BenzingaT3·9mo ago
BenzingaT3·9mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
12 of 12 under expected move
Avg Expected Move
28.16%
Avg Actual Move
4.82%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-11-03 | Pre-Market | 32.19% | 1.74% | 0.05x | Within |
| 2023-05-11 | Pre-Market | 10.66% | 4.89% | 0.46x | Within |
| 2023-08-10 | Pre-Market | 12.51% | 6.38% | 0.51x | Within |
| 2023-11-06 | Pre-Market | 43.00% | 9.56% | 0.22x | Within |
| 2024-02-27 | Pre-Market | 35.49% | 3.24% | 0.09x | Within |
| 2024-05-09 | Pre-Market | 18.69% | 0.90% | 0.05x | Within |
| 2024-08-08 | Pre-Market | 12.76% | 1.02% | 0.08x | Within |
| 2024-11-07 | Pre-Market | 13.95% | 3.86% | 0.28x | Within |
| 2025-01-14 | After-Close | 10.31% | 1.03% | 0.10x | Within |
| 2025-05-08 | Pre-Market | 84.71% | 3.31% | 0.04x | Within |
| 2025-08-07 | After-Close | 32.84% | 19.07% | 0.58x | Within |
| 2025-11-06 | Pre-Market | 30.83% | 2.89% | 0.09x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
VTYX Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $2.48
7-DTE Move: $2.48
Days to Exp: 17 (2026-03-20)
Options Flow
Call Volume: 69
Put Volume: 273
P/C Volume: 3.957
BEARISH
Call OI: 37,570
Put OI: 26,468
P/C OI: 0.704
Total OI: 64,038
ATM Options Pricing
ATM Call: $0.03
ATM Put: $2.45
Call %: 0.2%
Put %: 17.5%
Chain Summary
Chain Volume: 3,504
Chain OI: 146,450
Last Updated: 3/3/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 92nd percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
92%
vs own history
GEX tilt
+0.87
OI-weighted, today
Vanna tilt
+0.99
δ-sensitivity to IV
Charm tilt
-0.99
δ-decay vs time
Vanna tilt +0.99: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.99: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 23 ATM contracts, 83k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
-64.1
pts
EXTREME
as of Mar 3 · ATM 109.2% / Wing 45.1%
30 DTE / 10d
—
—
pts
EXTREME
as of Mar 3 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$2.48Mar 3
Beta Analysis
Insufficient price history — listed 1827 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.
VTYX Institutional Ownership (13F)
Latest filings — 2025-12-31Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
VTYX Insider Trading (Form 4)
Latest: 2026-03-04Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-04 | Allison Hulme | Director | Disp (D) | −129,364 opt | — | EDGAR | |
| 2026-03-04 | Roy Gonzales | Senior VP, Finance | Disp (D) | −5,313 | — | EDGAR | |
| 2026-03-04 | Onaiza Cadoret-Manier | Director | Disp (D) | −129,364 opt | — | EDGAR | |
| 2026-03-04 | John Nuss | CHIEF SCIENTIFIC OFFICER | Disp (D) | −489,481 | — | EDGAR | |
| 2026-03-04 | William Richard White | Director | Disp (D) | −249,882 opt | — | EDGAR | |
| 2026-03-04 | Matthew Richard Moore | Chief Operating Officer | Disp (D) | −465,000 opt | — | EDGAR | |
| 2026-03-04 | Somu Subramaniam | Director | Disp (D) | −3,337,495 | — | EDGAR | |
| 2026-03-04 | Raju Mohan | CEO AND PRESIDENT | Disp (D) | −2,372,863 | — | EDGAR | |
| 2026-03-04 | Mark S Forman | Chief Medical Officer | Disp (D) | −6,000 | — | EDGAR | |
| 2026-03-04 | Sheila Gujrathi | Director | Disp (D) | −130,000 | — | EDGAR | |
| 2026-03-03 | Somu Subramaniam | Director | Other (J) | −694,718 | — | EDGAR | |
| 2025-12-19 | John Nuss | CHIEF SCIENTIFIC OFFICER | Mixed | +22,255 | $7.72 | -$97.8K | EDGAR |
| 2025-12-19 | Raju Mohan | CEO AND PRESIDENT | Mixed | +69,323 | $7.72 | -$365.5K | EDGAR |
| 2025-11-19 | Roy Gonzales | Senior VP, Finance | Award (A) | +1,767 | $1.03 | $1.8K | EDGAR |
| 2025-11-19 | Mark S Forman | Chief Medical Officer | Award (A) | +3,000 | $1.03 | $3.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
VTYX Insider Holdings
1 insider · @ $13.99
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | William Richard White | Director | 7,027 | $98.3K | -$1.17M | 8 | 2026-03-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
VTYX Board & Officers
As of SEC filings through Mar 4, 2026Changes in the last 10 years (52)
| Mar 4, 2026 | William Richard White reported in an SEC filing no longer being a director |
| Mar 4, 2026 | Somu Subramaniam reported in an SEC filing no longer being a director |
| Mar 4, 2026 | Sheila Gujrathi reported in an SEC filing no longer being a director |
| Mar 4, 2026 | Roy Gonzales reported in an SEC filing no longer being Senior VP, Finance |
| Mar 4, 2026 | Raju Mohan reported in an SEC filing no longer being a director |
| Mar 4, 2026 | Raju Mohan reported in an SEC filing no longer being CEO and President |
| Mar 4, 2026 | Onaiza Cadoret-Manier reported in an SEC filing no longer being a director |
| Mar 4, 2026 | Matthew Richard Moore reported in an SEC filing no longer being Chief Operating Officer |
| Mar 4, 2026 | Mark S Forman reported in an SEC filing no longer being Chief Medical Officer |
| Mar 4, 2026 | John Nuss reported in an SEC filing no longer being Chief Scientific Officer |
| Mar 4, 2026 | Allison Hulme reported in an SEC filing no longer being a director |
| Mar 12, 2025 | Somu Subramaniam no longer listed as a 10% owner in SEC filings |
| Aug 30, 2024 | Roy Gonzales became Senior VP, Finance |
| Aug 12, 2024 | Mark S Forman became Chief Medical Officer |
| May 16, 2024 | Matthew Richard Moore became Chief Operating Officer |
| Apr 3, 2024 | The company announced the departure of Christopher W Krueger as Chief Business Officer in an SEC filing |
| Dec 19, 2023 | Raju Mohan listed as CEO and President (previously Chief Executive Officer) in SEC filings |
| Jan 11, 2023 | The company announced the departure of Jigar Choksey from the board in an SEC filing |
| Jan 11, 2023 | Onaiza Cadoret-Manier became a director |
| Jan 11, 2023 | Allison Hulme became a director |
| Jun 10, 2022 | Venbio Global Strategic Gp III, Ltd first listed as a 10% owner in an SEC filing |
| Jun 10, 2022 | Venbio Global Strategic Gp III, L.p. first listed as a 10% owner in an SEC filing |
| Jun 10, 2022 | Robert J Adelman first listed as a 10% owner in an SEC filing |
| Jun 10, 2022 | Corey S Goodman first listed as a 10% owner in an SEC filing |
| Jun 10, 2022 | Aaron Royston no longer listed as a 10% owner in SEC filings |
| May 9, 2022 | William J. Sandborn became President and Chief Medical Officer |
| May 5, 2022 | The company announced the departure of Jorn Drappa as Chief Medical Officer in an SEC filing |
| Oct 27, 2021 | Cormorant Private Healthcare Fund III LP reported in an SEC filing no longer being a 10% owner |
| Oct 27, 2021 | Cormorant Global Healthcare Master Fund, LP reported in an SEC filing no longer being a 10% owner |
| Oct 27, 2021 | Cormorant Asset Management, LP reported in an SEC filing no longer being a 10% owner |
| Oct 27, 2021 | Bihua Chen reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2021 | William Richard White became a director |
| Oct 20, 2021 | Somu Subramaniam became a director |
| Oct 20, 2021 | Somu Subramaniam became a 10% owner |
| Oct 20, 2021 | Sheila Gujrathi became a director |
| Oct 20, 2021 | Richard Gaster became a director |
| Oct 20, 2021 | Raju Mohan became a director |
| Oct 20, 2021 | Raju Mohan became Chief Executive Officer |
| Oct 20, 2021 | NSV Partners III LP became a 10% owner |
| Oct 20, 2021 | NSV Partners III GP LLC became a 10% owner |
| Oct 20, 2021 | NSV Investments I, L.P. became a 10% owner |
| Oct 20, 2021 | Martin Auster became Chief Financial Officer |
| Oct 20, 2021 | Jorn Drappa became Chief Medical Officer |
| Oct 20, 2021 | John Nuss became Chief Scientific Officer |
| Oct 20, 2021 | Jigar Choksey became a director |
| Oct 20, 2021 | Cormorant Private Healthcare Fund III LP became a 10% owner |
| Oct 20, 2021 | Cormorant Global Healthcare Master Fund, LP became a 10% owner |
| Oct 20, 2021 | Cormorant Asset Management, LP became a 10% owner |
| Oct 20, 2021 | Christopher W Krueger became Chief Business Officer |
| Oct 20, 2021 | Bihua Chen became a 10% owner |
| Oct 20, 2021 | Aaron Royston became a director |
| Oct 20, 2021 | Aaron Royston became a 10% owner |
Not reported recently (11)
- NSV Partners III LP · Last reported as a 10% owner in an SEC filing dated Jun 26, 2024
- NSV Partners III GP LLC · Last reported as a 10% owner in an SEC filing dated Jun 26, 2024
- Martin Auster · Last reported as Chief Financial Officer in an SEC filing dated Apr 3, 2024
- William J. Sandborn · Last reported as President and Chief Medical Officer in an SEC filing dated Sep 1, 2023
- Aaron Royston · Last reported as a director in an SEC filing dated Apr 26, 2023
- NSV Investments I, L.P. · Last reported as a 10% owner in an SEC filing dated Dec 15, 2022
- Richard Gaster · Last reported as a director in an SEC filing dated Jun 10, 2022
- Venbio Global Strategic Gp III, Ltd · Last reported as a 10% owner in an SEC filing dated Jun 10, 2022
- Corey S Goodman · Last reported as a 10% owner in an SEC filing dated Jun 10, 2022
- Robert J Adelman · Last reported as a 10% owner in an SEC filing dated Jun 10, 2022
- Venbio Global Strategic Gp III, L.p. · Last reported as a 10% owner in an SEC filing dated Jun 10, 2022
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
VTYX Proposed Insider Sales (Form 144)
Latest: 2025-12-18
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-12-18 | Mohan Raju | Officer, Director | 47,345 | $365.5K | 2025-12-18 | E-TRADE FINANCIAL CORPORATION | — | EDGAR |
| 2025-12-18 | Nuss John | Officer | 12,675 | $97.8K | 2025-12-18 | E-TRADE FINANCIAL CORPORATION | — | EDGAR |
| 2024-12-27 | Nuss John | Officer | 21,119 | $49.8K | 2024-12-27 | MORGAN STANLEY SMITH BARNEY LLC … | — | EDGAR |
| 2024-12-19 | Nuss John | Officer | 13,161 | $29.7K | 2024-12-19 | E-Trade Financial Corporation | — | EDGAR |
| 2024-04-02 | Krueger Christopher W | Officer | 1,651 | $8.9K | 2024-04-02 | E-TRADE FINANCIAL CORPORATION | — | EDGAR |
| 2024-04-02 | Nuss John | Officer | 1,651 | $8.9K | 2024-04-02 | E-TRADE FINANCIAL CORPORATION | — | EDGAR |
| 2024-04-02 | Mohan Raju | Officer, Director | 4,312 | $23.3K | 2024-04-02 | E-TRADE FINANCIAL CORPORATION | — | EDGAR |
| 2024-04-02 | Auster Martin | Officer | 1,405 | $7.6K | 2024-04-02 | E-TRADE FINANCIAL CORPORATION | — | EDGAR |
| 2023-12-20 | Mohan Raju | Officer, Director | 58,860 | $124.7K | 2023-12-20 | E-TRADE FINANCIAL CORPORATION | — | EDGAR |
| 2023-12-20 | Krueger Christopher W | Officer | 5,293 | $11.2K | 2023-12-20 | E-TRADE FINANCIAL CORPORATION | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.86M
SI % of Float
9.48%
Days to Cover
1.24
Short Vol Ratio
41.1%
Free Float
51.27M
Float %
71.5%
Short interest 2026-02-27 • Short volume 2026-03-03 • Float 2026-02-09